CLOUDBREAK-B (02592) saw a sharp decline of nearly 15%, extending its retreat to over 40% since December 5. Notably, the stock had surged significantly from November 21 to December 4, doubling in just 10 trading sessions. As of press time, the stock was down 11.59% at HK$4.96, with a turnover of HK$6.78 million.

On the news front, CLOUDBREAK announced that on December 15, its wholly-owned subsidiary, ADS Therapeutics LLC, submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-199, a potential best-in-class ophthalmic drug candidate developed by the group. CBT-199 has been undergoing safety and tolerability assessments in preclinical animal studies since June 2023, with the findings expected to support future clinical trials.

Additionally, it is worth noting that on January 3, two cornerstone investors of CLOUDBREAK-B will see their lock-up shares become tradable.